The firm will use the proceeds from the offering for product development efforts and to further its efforts to obtain US Food and Drug Administration clearance of its stool-based DNA colorectal cancer screening product.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.